TLR9 and systemic lupus erythematosus: Based on IHN-ODN 2088, a guanine-modified inhibitory oligonucleotide, INH-ODN-24888, was designed; this compound demonstrated a promising therapeutic effect in SLE through the suppression of both TLR7 and TLR9 (Rommler et al., 2015).